Clopidogrel - KDT (KD Tripathi) Style

Note: KD Tripathi's Essentials of Medical Pharmacology is not directly available in the textbook library. The following is compiled from equivalent authoritative pharmacology references - Katzung's Basic & Clinical Pharmacology (16e), Lippincott Illustrated Reviews: Pharmacology, Harrison's Principles of Internal Medicine 22e, and Braunwald's Heart Disease - covering all KDT-relevant content.

Classification

Mechanism of Action

1. After oral ingestion, clopidogrel is converted to an active thiol metabolite via CYP2C19.
2. The active metabolite irreversibly and selectively blocks the P2Y12 ADP receptor on the platelet surface.
3. Normally, ADP binds P2Y12 → activates GP IIb/IIIa receptors → platelets bind fibrinogen → platelet aggregation occurs.
4. By blocking P2Y12, clopidogrel prevents ADP-induced activation of GP IIb/IIIa receptors, thereby inhibiting platelet aggregation.
5. Since binding is irreversible, the antiplatelet effect lasts for the entire platelet lifespan (~7-10 days).

• Unlike aspirin, clopidogrel has no effect on prostaglandin/thromboxane metabolism.
• The block is irreversible - platelet function returns only when new platelets are generated.
• Maximum platelet inhibition with the 75 mg/day maintenance dose is achieved in 3-5 days; a loading dose of 300-600 mg produces 80% inhibition within 5 hours.

Pharmacokinetics

Uses / Therapeutic Indications

1. Acute Coronary Syndromes (ACS):
   • Unstable angina / NSTEMI: Loading dose 300 mg + aspirin, then 75 mg/day (dual antiplatelet therapy - DAPT)
   • STEMI: 75 mg/day with aspirin
2. Post-PCI / Coronary Stenting:
   • After bare metal stent: DAPT for at least 4 weeks
   • After drug-eluting stent: DAPT for at least 1 year
3. Secondary prevention of atherosclerotic events:
   • Recent MI, recent ischemic stroke, or established peripheral arterial disease (PAD)
   • Clopidogrel is more effective than aspirin in this setting (8.7% relative risk reduction vs aspirin for cardiovascular death, MI, or stroke - CAPRIE trial)
4. As an aspirin alternative in patients intolerant to aspirin (e.g., GI intolerance)

Adverse Effects

Important Drug Interactions:

• Omeprazole / Esomeprazole (CYP2C19 inhibitors): Reduce conversion of clopidogrel to active metabolite → reduced antiplatelet efficacy - should be avoided or used cautiously
• Aspirin: Additive antiplatelet effect (benefit in ACS/stenting), but increases bleeding risk to ~2%/year
• CYP2C19 inducers: May increase active metabolite formation
• Opioids: May decrease clopidogrel exposure

Contraindications

• Active pathological bleeding (peptic ulcer, intracranial hemorrhage)
• Hypersensitivity to the drug

Comparison with Ticlopidine (KDT-relevant point)

Key Points for Exams (KDT Style)

• Clopidogrel = thienopyridine prodrug, activated by CYP2C19
• Irreversible blockade of P2Y12 ADP receptor on platelets
• Prevents GP IIb/IIIa activation → blocks fibrinogen binding → inhibits platelet aggregation
• No prostaglandin pathway effect (unlike aspirin)
• Bleeding is the most important adverse effect - no antidote
• Avoid omeprazole/esomeprazole (CYP2C19 inhibitors reduce drug activation)
• CYP2C19 poor metabolizers → clopidogrel resistance → switch to prasugrel or ticagrelor
• Loading dose: 300-600 mg; Maintenance: 75 mg once daily
• Duration of antiplatelet effect after stopping: 7-10 days (platelet turnover time)